Marker Therapeutics (MRKR) Expected to Announce Quarterly Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.6820 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Marker Therapeutics Price Performance

NASDAQ MRKR opened at $1.38 on Friday. The stock’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $1.28. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The firm has a market cap of $23.00 million, a PE ratio of -1.12 and a beta of 1.42.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new position in shares of Marker Therapeutics during the fourth quarter valued at $222,000. Osaic Holdings Inc. boosted its holdings in Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after acquiring an additional 13,340 shares during the last quarter. Renaissance Technologies LLC increased its position in Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the period. Geode Capital Management LLC increased its position in Marker Therapeutics by 35.3% in the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after purchasing an additional 34,028 shares during the period. Finally, XTX Topco Ltd raised its holdings in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the last quarter. Institutional investors own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on MRKR. UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. HC Wainwright assumed coverage on Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. Finally, Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.